Compare TCMD & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCMD | EOLS |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.9M | 500.0M |
| IPO Year | 2016 | 2018 |
| Metric | TCMD | EOLS |
|---|---|---|
| Price | $23.44 | $7.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $37.67 | $15.00 |
| AVG Volume (30 Days) | 167.8K | ★ 665.0K |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.14 | 1.23 |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $9.98 | $12.44 |
| Revenue Next Year | $9.44 | $17.37 |
| P/E Ratio | $91.00 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $14.84 | $3.86 |
| 52 Week High | $37.77 | $9.31 |
| Indicator | TCMD | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 40.67 |
| Support Level | $22.92 | $7.07 |
| Resistance Level | $27.67 | $7.28 |
| Average True Range (ATR) | 0.60 | 0.32 |
| MACD | 0.18 | -0.03 |
| Stochastic Oscillator | 81.96 | 23.66 |
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.